Laszlo Urban is Global Head of Preclinical Secondary Pharmacology (PSP) at the Novartis Institutes for Biomedical Research (NIBR), Cambridge, MA, USA. He has been with Sandoz/Novartis since 1990, leading various global pharmaceutical research areas. As the founding leader of PSP, he developed and implemented the early in vitro preclinical secondary pharmacology profiling program for NIBR.
He and his team are developing “safety assessment tools for decision support” which provide access to integrated information for adverse drug reaction (ADR) mitigation. Laszlo received his M.D. and Ph.D. in neuropharmacology from Debrecen University, Hungary. He is Honorary Lecturer of the University College London and was a visiting professor at Duke University. He has published over 180 articles, book chapters and patents, edited 5 books and has served on the editorial board of several journals while also serving as President of the European Neuropeptide Club.